Navigation Links
BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
Date:12/5/2008

BELLUS Health Receives NASDAQ Deficiency Notice Relating to Market Value

------------------------------------------------------------------------

LAVAL, QC, Dec. 5 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces that in light of continuing significant fluctuations in world capital markets, the Company is preparing to voluntarily delist from the NASDAQ Capital Market, while continuing to maintain a full listing on the Toronto Stock Exchange (TSX: BLU). In connection with its NASDAQ listing, the Company received a Deficiency Letter dated December 1, 2008, from the NASDAQ Staff stating that, for 10 consecutive trading days, the market value of the Company's listed securities had been below the minimum $35,000,000 requirement for continued inclusion on the NASDAQ Capital Market under Marketplace Rule 4310(c)(3)(B), and that the Company would have until December 31, 2008 to regain compliance. The Company's listing on the Toronto Stock Exchange is not affected by the notice received from NASDAQ, nor by the decision to voluntarily delist from this U.S. exchange. The Company expects the delisting to take effect in early January 2009. The Company will continue to be subject to the filing and other obligations of the U.S. securities laws applicable to non-U.S. reporting companies during 2009.

The decision to voluntarily delist is reinforced by extreme short-term volatility in stock markets and accordingly, in the Company's market value. Daily fluctuations in the price of BELLUS Health shares have resulted in the Company moving in and then out of compliance with NASDAQ requirements over the past weeks. In light of the recent correspondence with NASDAQ, BELLUS Health has determined that the perceived benefit of being listed on NASDAQ no longer merits the capital and human investment involved in maintaining the
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
2. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
3. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
4. BELLUS Health provides update on activities
5. BELLUS Health announces closing of Innodia acquisition
6. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
7. BELLUS HEALTH reports results for first quarter of fiscal 2008
8. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
9. Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices
10. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
11. Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...TY, Jan. 8 In response to a critic...nationwide, ARUP Laboratories, a national medical ...boratory research and development, and Weber Stat...rning arena, have partnered to promote and facilit...d medical laboratory technicians (MLT). ARUP and W...
(Date:1/8/2009)...f Government Officials Expect to Maintain or Incre...onstruction of Roads and Bridges, Creation of 21st...icient Government Facilities , , SEATTLE, Jan. ... Obama,s economic stimulus package outlines a sign...ady" construction of roads and bridges, 21st-centu...
(Date:1/8/2009)...ncy reception sets stage for productive partnershi...icare Advocacy Recovery Coalition (MARC), a broad-...or reform, laid the groundwork for improving the M...gural meeting with officials from the Center for M...urpose was to introduce MARC as an industry resour...
(Date:1/8/2009)...n linguistic and cultural differences of native pe...ws) -- Genetic evidence suggests that two differen...a at about the same time to become the first settl...oximately 15,000 to 17,000 years ago, one group of...dmass, which once connected northeast Siberia to A...
Breaking Medicine News(10 mins):Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 2Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 3Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 4Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 2Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 3Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 4Health News:MARC Coalition Holds Initial Meeting With CMS; Announces New Members 2Health News:First Americans Arrived on 2 Separate Paths 2
...harmless, but it looks awful. Worse, it's a real p...ngue (lingua villosa nigra) occurs when the papill...row up to 1.5 cm in length and turn black or brown... the University of Essen. It occurs most regularly...
...een geographic convenience and the quality of serv...remote areas, according to an article// in the lat...JA). There is a developing trend towards urban ce...rvices, driven by a need to maintain service quali...
...c survey conducted by Dr. David Schutt of Thomson ...m it was found that more than three-quarters// of ...are healthy. About 11,000 people were contacted b...hey did vigorous exercise for times a week. About ...
...e 2 diabetes could also be at risk of chronic kidn...test issue of the Medical Journal of Australia.// ... of Renal Impairment cO-existing with NIDDM (non-i...is one of the largest studies of type 2 diabetes e...
Other Medicine News:Health News:Bolster Rural Surgical Services 2
(Date:1/6/2009)...swire-USNewswire/ -- Sequella, Inc., a clinical-st...of epidemic potential, announced today that SQ109,...rculosis (TB), was the first drug approved for eva...ct to Dynport Vaccine Company LLC and Quintiles Tr... Institute of Allergy and Infectious Diseases (NIA...
(Date:1/5/2009).../ -- Cylene Pharmaceuticals announced today that i...al CK2 protein kinase inhibitor, CX-4945, in patie...e, or multiple myeloma. The primary endpoints of t... safety, tolerance and PK properties of CX-4945 an...ls. In addition, multiple mechanism-related pharma...
(Date:12/30/2008)...re-USNewswire/ -- The Coalition for 21st Century M...d by Genentech, Inc. on December 5, 2008, seeking ...iagnostic tests to physicians and patients. The r...ould harm patient care and rests on flawed scienti...sion is to encourage the research, development, an...
(Date:12/27/2008)...year silence, offers to ease cloning costs for Clo..., Dec. 27 Six years to ...ned child, Dr. Brigitte Boisselier, head of the co... other babies cloned by her company are growing up...ir families, privacy. , , "We,ve helped almost ...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4'We're Ready to Prove It!' 2Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis 28046 1Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis 28046 2Cardinal Health Reports First Quarter Results 28043 1Cardinal Health Reports First Quarter Results 28043 2Cardinal Health Reports First Quarter Results 28043 3Cardinal Health Reports First Quarter Results 28043 4Cardinal Health Reports First Quarter Results 28043 5Cardinal Health Reports First Quarter Results 28043 6Cardinal Health Reports First Quarter Results 28043 7Cardinal Health Reports First Quarter Results 28043 8Cardinal Health Reports First Quarter Results 28043 9Cardinal Health Reports First Quarter Results 28043 10Cardinal Health Reports First Quarter Results 28043 11Cardinal Health Reports First Quarter Results 28043 12Cardinal Health Reports First Quarter Results 28043 13Cardinal Health Reports First Quarter Results 28043 14Cardinal Health Reports First Quarter Results 28043 15Cardinal Health Reports First Quarter Results 28043 16Cardinal Health Reports First Quarter Results 28043 17Cardinal Health Reports First Quarter Results 28043 18Cardinal Health Reports First Quarter Results 28043 19Cardinal Health Reports First Quarter Results 28043 20Cardinal Health Reports First Quarter Results 28043 21Cardinal Health Reports First Quarter Results 28043 22Cardinal Health Reports First Quarter Results 28043 23DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 1DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 2DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 3DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 4CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011 vcMMAE Phase II Trial Results on November 3 200 3360 1CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011 vcMMAE Phase II Trial Results on November 3 200 3360 2
...ity Biotech Captia™ Mumps IgG Enzyme-linked Im...ction and quantitative determination of IgG antibo...specimens may be used for the determination of imm...ay be used to demonstrate seroconversion or a sign...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in
...nal treatment of diseases of the thoracic aorta ha...ision in the chest to place a synthetic graft to r...in long hospital stays and painful recoveries. Tod... alternatives to this major open surgical approach...
...lagship product, the Super Premium ALPHA 10 System... versatility in an intuitive and ergonomically des...tem for Perinatology/Maternal & Fetal Medicine Spe...ons, Breast Imaging, and General Imaging departmen...
Medicine Products: